Sebastian Schaefer

This inventor holds 26 USPTO granted patents and 14 published patent applications and 5 EPO patents, primarily in Cytokine Therapy. Top assignees: National University of Singapore, Singapore Health Services Pte Ltd, Boehringer Ingelheim International Gmbh. Active years: 2018-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Sebastian Schaefer. Retrieved from https://idiyas.com/inventor/sebastian-schaefer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26 (Patent Applications = 14)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 22)

Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 56(Granted Patents)

Company Filing History:

26 out of 857

National University of Singapore

patents

26 out of 140

Singapore Health Services Pte Ltd

patents

2 out of 1,562

Boehringer Ingelheim International Gmbh

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

Areas of Expertise:

Cytokine Receptor

IL-11 Antibodies

Fibrosis Treatment

Metabolic Diseases

Kidney Injury

Hepatotoxicity

Interleukin-11

Antibody Therapy

SMC Mediated Disease

Therapeutics

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12240889 - Decoy cytokine receptor (2025-03-04),

2. 12234284 - Treatment of kidney injury (2025-02-25),

3. 11939374 - Treatment of fibrosis (2024-03-26),

4. 11813311 - Treatment and prevention of metabolic diseases (2023-11-14),

5. 11780898 - Treatment of SMC mediated disease (2023-10-10),

6. 11339216 - Treatment of kidney injury (2022-05-24),

7. 11319368 - Treatment of hepatotoxicity with IL-11 antibody (2022-05-03),

8. 11274143 - Decoy cytokine receptor (2022-03-15),

9. 11084878 - IL-11Rα antibodies (2021-08-10),

10. 11084874 - IL-11 antibodies (2021-08-10),

11. 11078269 - IL-11Rα antibodies (2021-08-03),

12. 11078268 - IL-11 antibodies (2021-08-03),

13. 10927169 - Treatment of fibrosis with Interleukin-11 receptor alpha antibody (2021-02-23),

14. 10899832 - Treatment of fibrosis with interleukin-11 receptor alpha antibody (2021-01-26),

15. 10894827 - Treatment of fibrosis with interleukin-11 receptor alpha antibody (2021-01-19),

As an AI assistant specialized in innovations, inventions, inventors, patent attorneys, assignees, and patents, I understand you are interested in learning more about the inventor Sebastian Schaefer from Singapore, SG, with 24 patents.

Title: Unveiling the Innovator - Sebastian Schaefer

Introduction:

Sebastian Schaefer, a prolific inventor based in Singapore, SG, has made significant contributions to the field of medicine with his groundbreaking patents and innovative research.

Latest Patents:

Sebastian's latest patents revolve around cutting-edge treatments in the medical field. His patents include "Treatment of fibrosis" which focuses on combating conditions like fibrosis in subjects by inhibiting the action of Interleukin 11 (IL-11) and "Treatment and prevention of metabolic diseases" through inhibiting IL-11-mediated signaling.

Career Highlights:

Sebastian has showcased his expertise while working at prominent institutions such as Singapore Health Services Pte Ltd and the National University of Singapore. His dedication to advancing medical treatments has led to the development of life-changing solutions in the healthcare industry.

Collaborations:

Throughout his career, Sebastian has collaborated with notable professionals like Stuart Alexander Cook and Anissa Anindya Widjaja. These collaborations have been instrumental in the success of his patent applications and the development of groundbreaking innovations.

Conclusion:

In conclusion, Sebastian Schaefer's relentless pursuit of innovation in the medical field has not only resulted in numerous patents but has also positively impacted the lives of many. His contributions stand as a testament to his commitment to pushing the boundaries of medical science and improving healthcare outcomes globally.

Profile summary based on public USPTO records.